EGFR and non-small cell lung carcinoma: Positive results have also been obtained from phase III research (AENEAS) that compared the safety and effectiveness of aumolertinib to gefitinib, as a first-line treatment for patients with locally progressed or metastatic NSCLC with EGFR mutations [46].